Due to antigen heterogeneity, restricted immune cell trafficking and an immunosuppressive, nutrient-restricted tumour microenvironment, solid tumours remain resistant to modern immunotherapies. Engineered bacteriophages offer a modular framework to overcome these obstacles: programmable virus-like particles with scalab...
Overall, CAR T cell therapy beyond oncology is promising but remains preliminary, requiring standardized reporting, long-term safety monitoring, scalable manufacturing, and carefully defined risk–benefit thresholds.
Kawther A. Zaher, J. Alrahimi· Pathophysiology· 0 citations
IL-6 alone showed a modest, unadjusted association with disability, supporting its evaluation as a candidate biomarker in larger, longitudinal, covariate-adjusted cohorts, and these findings are hypothesis-generating and should not be interpreted as evidence of independent or clinically actionable biomarker utility.
J. Alrahimi, Yara Mualla, A. Alhebshi et al.· Neurology International· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.